radiation – Page 15 – Oral Cancer News

Smokers are 40 times more likely to develop cancers in head and neck

Source: www.heraldandnews.com Author: Andrew Creasey, Staff Reporter The level of concern you should have for contracting cancer of the head and neck can be gauged by the answer to one simple question: Do you smoke? If the answer is no, chances are your oral cavities and voice box, the places cancers most commonly occur, will be safe from the onerous growth that can cause death if not treated soon enough. If the answer is yes, then you are 40 times more likely to contract head or neck cancer if you have been smoking for 10 years, and you should probably be aware of what to look for, said Dr. Richard DeVore, an otolaryngologist in Klamath Falls. Signs of head and neck cancer include a sore or ulcer that doesn’t heal, unexplained bleeding of the throat and, most importantly, throat or tongue pain that persists beyond several weeks, DeVore said. Such pain could be caused by the cancer, which actually eats into the tissue and can cause significant pain when it starts munching on the local nerves. Swallowing difficulties, hoarseness and lumps in the head and neck that don’t respond to antibiotics should also be examined, DeVore said. At the onset of such symptoms, it is vital to share them with a physician, DeVore said. Caught early, the cure rate of many neck and head cancers is 100 percent and can be solved with a simple operation. “The cure rates are slowly improving to some degree, but it’s a bad disease,” [...]

Oral Cancer Foundation News Team - A2012-10-23T07:51:35-07:00October, 2012|Oral Cancer News|

Interim results from CEL-SCI’s Multikine Phase III study on head and neck cancer

Source: www.news-medical.net CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns. The IDMC also indicated that no safety signals were found that would call into question the benefit/risk of continuing the study. CEL-SCI considers the results of the IDMC review to be important since studies have shown that up to 30% of Phase III trials fail due to safety considerations and the IDMC's safety findings from this interim review were similar to those reported by investigators during CEL-SCI's Phase I-II trials. Ultimately, the decision as to whether a drug is safe is made by the FDA based on an assessment of all of the data from a trial. IDMCs are committees commonly used by sponsors of clinical trials to protect the interests of the patients in ongoing trials especially when the trials involve patients with life threatening diseases, and when, as in cancer clinical trials, they extend over long periods of time (3-5 years). The committee's membership should include physicians and clinical trial scientists knowledgeable in the appropriate disciplines, including statistics. The CEL-SCI IDMC includes prominent physicians and scientists from major institutions in the USA and abroad who are key opinion leaders in head and neck cancer and who are knowledgeable in all of the disciplines related to CEL-SCI's study, including statistics. The Multikine Phase III study is enrolling [...]

Oral Cancer Foundation News Team - A2012-10-23T07:33:16-07:00October, 2012|Oral Cancer News|

No ref’s return as special as Corrente’s

Source: sportsillustrated.cnn.com Author: Peter King The voice of Tony Corrente was ebullient, as ebullient as a man who stared down his own mortality within the past few months and lived to tell about it. "How are you doing?'' I asked Corrente an hour after he refereed his first game -- Niners-Jets at the Meadowlands Sunday -- since his tongue and throat cancer eradication of last winter. "Wonderful, fantastic, perfect!'' he practically shouted into the phone. "Never been better, and I mean that. I am elated. I have a new lease on life." Corrente checked into the M.D. Anderson Cancer Center in Houston the day after his final game of the 2011 season -- the Detroit-New Orleans Wild Card game -- for treatment of a thumb-sized malignant tumor at the base of his tongue, where it connects with the back of his throat. He had 13 chemotherapy treatments and 33 zaps of radiation in a short period, to attack the tumor aggressively. Doctors told him if the tumor had been discovered as little as three weeks later the news would have been very dark for him. But they began treatment in time, and in the spring, they found that the tumor was under control. He's had two thorough checkups since, and both have given him a clean bill of health. This is why, as the National Anthem played Sunday in New Jersey, Corrente said a long prayer of thanks for his doctors and for those who supported him during the ordeal. [...]

Oral Cancer Foundation News Team - A2012-10-07T15:54:02-07:00October, 2012|Oral Cancer News|

It Costs More, but Is It Worth More?

Source: The New York Times- Opinion Pages By EZEKIEL J. EMANUEL and STEVEN D. PEARSON If you want to know what is wrong with American health care today, exhibit A might be the two new proton beam treatment facilities the Mayo Clinic has begun building, one in Minnesota, the other in Arizona, at a cost of more than $180 million dollars each. They are part of a medical arms race for proton beam machines, which could cost taxpayers billions of dollars for a treatment that, in many cases, appears to be no better than cheaper alternatives. Proton beam therapy is a kind of radiation used to treat cancers. The particles are made of atomic nuclei rather than the usual X-rays, and theoretically can be focused more precisely on cancerous tissue, minimizing the danger to healthy tissue surrounding it. But the machines are tremendously expensive, requiring a particle accelerator encased in a football-field-size building with concrete walls. As a result, Medicare will pay around $50,000 for proton beam therapy for a patient with prostate cancer, roughly twice as much as it would if the patient received another type of radiation. The higher price would be worth it if proton beam therapy cured more people or significantly reduced side effects. But there is no evidence showing that this is true, except for a handful of rare pediatric cancers, like brain and spinal cord cancer. For children, the treatment does a better job of limiting damage to normal brain cells and reducing the [...]

Charlotte Parker2012-08-28T09:24:52-07:00August, 2012|Oral Cancer News|

Salivary glands project offers hope for head and neck cancer patients

Source: Dental-Tribune.com Researchers have shown that salivary cells cultured outside the body can be coaxed into forming organized structures similar to those found in the body. These images show cells marked with fluorescent dyes that identify specific proteins found in salivary tissues. (DTI/Photo courtesy of Swati Pradhan-Bhatt/University of Delaware) HOUSTON, Texas/NEWARK & WILMINGTON, Del., USA: Scientists in the U.S. have started a four-year program with the aim of regenerating artificial salivary glands from patients' own cells. As few researchers have applied tissue-engineering strategies in the past, they hope that their current work will lead to new solutions for cancer patients suffering from dry mouth as a consequence of radiation therapy. The researchers estimate that about 40,000 head and neck cancer patients undergo standard radiation as an early course of treatment each year, which often destroys the saliva-producing cells in their mouths. Consequently, patients have difficulty swallowing, eating and speaking owing to dry mouth, a serious condition that is also known to accelerate tooth decay and to induce oral infections. "There is currently no way to prevent or cure xerostomia for cancer patients who are undergoing radiation therapy. This is clearly a problem where regenerative medicine holds great promise for improving the quality of life for many people," said Dr. Robert Witt, a head and neck surgical oncologist at the Helen F. Graham Cancer Center. For the project, the team developed a technique to harvest and grow salivary acinar cells, which are responsible for water and enzyme production, in the [...]

Charlotte Parker2012-08-21T18:54:05-07:00August, 2012|Oral Cancer News|

New Guidelines for Head & Neck Cancer Reirradiation

Source: PhysciansWeekly.com Recurrent and second primary head-and-neck squamous cell carcinomas arising within or close to previously irradiated areas are a significant clinical challenge. The American College of Radiology published appropriateness criteria for recurrent head and neck cancer after prior definitive radiation. Recurrent and second primary head-and-neck squamous cell carcinomas (HNSCC) arising within or close to previously irradiated areas are a significant clinical challenge. Salvage surgical resection is the standard of care, but reirradiation is the only potentially curative treatment when surgery is not an option. Reirradiation is more challenging than initial treatment because of the side effects of prior therapy and concerns about the risks of high cumulative radiation doses to normal structures. Multi-institutional trials and large single institutional experiences have demonstrated that aggressive reirradiation, most often with chemotherapy, is feasible and provides durable locoregional control in some patients. An Expert Consensus on Reirradiation In the August 1, 2011 International Journal of Radiation Oncology * Biology * Physics, the American College of Radiology (ACR) published appropriateness criteria for recurrent head and neck cancer after prior definitive radiation. The ACR expert panel recommended that patient evaluation and reirradiation for HNSCC be performed at a tertiary care center with a head and neck oncology team that is equipped with the resources and experience to manage the complexities and toxicities of retreatment. Evaluation of Patients with Head & Neck Cancer Patient evaluation is important in assuring only appropriate patients are offered reirradiation. Evaluation should include careful restaging imaging, a detailed history and assessment [...]

Charlotte Parker2012-08-20T10:43:31-07:00August, 2012|Oral Cancer News|

Robotic surgery vs. radiation therapy: study will find which better for throat cancer

Source: http://www.windsorstar.com/ Author: Beatrice Fantoni, The Windsor Star In the first trial of its kind in the world, doctors in London, Ont., are comparing robotic surgery and radiation therapy to find out which method helps throat-cancer patients retain speech and swallowing functions - two very important functions that can have a serious effect on quality of life for cancer survivors. Dr. Anthony Nichols and Dr. David Palma of the London Health Sciences Centre are working with 68 test subjects who have cancer of the back of the throat (also known as oropharyngeal cancer) and measuring the swallowing functions of each patient one year after treatment. Because the cure rate for oropharyngeal cancer is pretty good, Nichols said, he and Palma want to focus on how to improve patients' post-treatment quality of life. In Canada, the standard way of treating oropharyngeal cancer is with a combination of radiation and chemotherapy. However, Nichols said, there can be some longterm side-effects with this treatment, such as dry mouth, hearing loss, taste changes and compromised swallowing function. "The side-effects are more than what we'd like," said Palma. "We want to improve the quality of life." Surgery using a robot is a newer treatment that could perhaps be more appropriate for some oropharyngeal cancer patients, Nichols said. London is currently the only site in Canada to offer what is known as transoral robotic surgery. The robot sounds promising, Palma said, and so it warrants more study. "We don't really know if the 'surgery first' approach [...]

Oral Cancer Foundation News Team - A2012-08-03T09:54:30-07:00August, 2012|Oral Cancer News|

The Impact of Timing of EGFR and IGF-1R Inhibition for Sensitizing Head and Neck Cancer to Radiation

Source: AntiCancer Research Abstract Background: Targeting the epidermal growth factor receptor (EGFR) improved radiotherapy outcome by 10-15% in head and neck tumors (HNSCC). We tested the therapeutic benefits of co-targeting EGFR and insulin-like growth factor-1 receptor (IGF-1R) to further enhance tumor response to radiation. Materials and Methods: Mice bearing FaDu tumor xenografts were treated with ganitumab (previously known as AMG479, an anti-IGF-1R antibody), panitumumab (an anti-EGFR antibody), or both in combination with fractionated doses of radiation. Tumor growth delay and tumor cure/recurrence served as end-points. Results: The best tumor growth delay was achieved when ganitumab and panitumumab were given concurrently with radiation. Tumor cure/recurrence studies showed that combining ganitumab, panitumumab and radiation resulted in significantly higher radiocurability rates than use of either of the agents given with radiation. Conclusion: These findings provide the rationale for clinical testing of the combination of ganitumab and panitumumab for the treatment of HNSCC. This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2012-07-26T09:29:45-07:00July, 2012|Oral Cancer News|

Western University profs to test robotic treatment of throat cancer

Source: metronews.ca Author: Josh Elliott Western University professors David Palma and Anthony Nichols will lead a first-ever study to see if robotic surgery can treat throat cancer while avoiding the long-term side effects that come with chemotherapy and radiation. Transoral robotic surgery (TORS) allows doctors to use miniature robotic arms to operate in tight spaces where human hands can’t fit. London has the only TORS program in Canada. Early stage oropharyngeal cancer patients will be randomly assigned standard radiation care, or the new TORS treatment. Doctors will measure long-term side effects and quality of life following both treatments. Oropharyngeal cancer affects the back of the throat. Radiation therapy is effective at controlling the cancer, but some patients still suffer long-term side effects such as dry throat, difficulty swallowing, and hearing loss. “In the U.S., TORS is being used readily in the treatment of oropharyngeal cancer, in spite of the lack of high-level evidence supporting the use,” said Nichols, a head and neck cancer surgeon at London Health Sciences Centre. Palma, a radiation oncologist at LHSC, says the Western study will compare TORS treatment to traditional radiation therapy. “Before we can implement TORS, we need to prove that it meets that standard: Are the cure rates just as good, and are the side effects less?” Nichols sees reason for optimism: “Early studies of TORS show it holds promise to provide good disease control, as well as offer good speech and swallowing outcomes for patients.”

Oral Cancer Foundation News Team - A2012-07-18T06:09:13-07:00July, 2012|Oral Cancer News|

Blacks with throat cancer get harsher therapy

Source: in.reuters.com Author: Frederik Joelving Blacks in the United States with throat cancer are more likely than whites to have surgery that leaves them unable to speak than to get gentler voice-preserving therapy, according to a study. Previous research has found a similar racial disparity in breast cancer treatment, with blacks more often having the entire breast removed instead of just the cancerous lumps. It's unclear why the disparity exists. But study leader Allen Chen, a radiation oncologist at University of California, Davis, said that poverty, less education and deep-rooted historical biases could all be at work. "There could be an underlying distrust among African Americans where they feel anything less than surgery might be considered quote-unquote experimental," Chen told Reuters Health. He referenced the Tuskegee experiment, conducted by the U.S. government from the 1930s into the 1970s, in which black patients with syphilis went untreated despite assurances to the contrary. "That sort of distrust needs to be addressed or alleviated," Chen said, because voice-preserving treatment for throat cancer, based on radiation and drug therapy, is now the standard. His study, published in the Archives of Otolaryngology - Head & Neck Surgery, is based on data from a US cancer registry including nearly 5,400 cases of laryngeal cancer between 1991 and 2008. About 80 percent of whites had voice-preserving treatment, while the rest had their voice box surgically removed - the traditional approach. Among blacks, 75 percent had the gentler therapy. While that's only a five-percent difference, "I think that's [...]

Oral Cancer Foundation News Team - A2012-07-18T06:04:33-07:00July, 2012|Oral Cancer News|